Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial
| Autor: | Mercedes Servigna, Edgardo Carrizo, Euderruh Uzcátegui, Tatiana Galeazzi, Marycelvia Uzcátegui, Nairy Rangel, Ana Serrano, María A. Gutiérrez, Serge Beaulieu, Enma Araujo de Baptista, Lisette Connell, Yamily El Fakih, Virginia Fernández, Trino Baptista, Adriana Dávila |
|---|---|
| Rok vydání: | 2007 |
| Předmět: |
Olanzapine
Adult Blood Glucose Leptin Male medicine.medical_specialty Bipolar Disorder medicine.drug_class Statistics as Topic Placebo-controlled study Atypical antipsychotic Placebo Body Mass Index Benzodiazepines Insulin resistance Double-Blind Method Diabetes mellitus Internal medicine medicine Brief Psychiatric Rating Scale Humans Hypoglycemic Agents Biological Psychiatry Glycated Hemoglobin Dose-Response Relationship Drug business.industry Body Weight nutritional and metabolic diseases Middle Aged medicine.disease Lipids Metformin Psychiatry and Mental health Endocrinology Adjunctive treatment Schizophrenia Drug Therapy Combination Female Insulin Resistance business Energy Metabolism medicine.drug Antipsychotic Agents |
| Zdroj: | Schizophrenia research. 93(1-3) |
| ISSN: | 0920-9964 |
| Popis: | Background Excessive body weight gain (BWG) is a clinically relevant side effect of olanzapine administration. The primary objective of this study was to assess whether metformin prevents or reverses BWG in patients with schizophrenia or bipolar disorder under olanzapine administration. Secondarily we evaluated diverse metabolic variables. Methods Eighty patients taking olanzapine (5–20 mg daily for more than 4 consecutive months) were randomly allocated to metformin (n = 40; 850 to 2550 mg daily) or placebo (n = 40) group in a 12-week double-blind protocol. Waist circumference (WC) body weight (BW), body mass index (BMI) fasting glucose, glycated hemoglobin (Hb1c), insulin, an insulin resistance index (HOMA-IR) lipids, leptin, c-reactive protein, fibrinogen, cortisol and the growth hormone (GH) were evaluated at baseline and at week 12 of treatment. Results The metformin group lost 1.4 ± 3.2 kg (p = 0.01) and tended to decrease its leptin levels, whereas the placebo group maintained a stable weight: − 0.18 ± 2.8 kg (p = 0.7). The HOMA-IR significantly increased after placebo (p = 0.006) and did not change after metformin (p = 0.8). No ostensible differences were observed in the other variables, even though metformin did not improve the lipid profile and the Hb1c levels. Conclusions Metformin may safely assist olanzapine-treated patients in body weight and carbohydrate metabolism control. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect